SavedAdd your journal

Journals / Retina-Vitreus / 2015 / Cilt: 23 - Sayı: 0

Anti-VEGF Treatment in Age Realted Macular Degeneration

Yaşa Bağlı Maküla Dejenerasyonunda Anti-VEGF Tedavisi

Ziya KAPRAN
Fırat HELVACIOĞLU
Pages
233–242
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This paper will review the currently available anti-VEGF agents and evidence-based treatment strategies

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Over the past few years, anti-VEGF therapy has become a gold standard treatment for neovascular age-related macular degeneration.
📊
Key Findings & Data:Treatment strategies have evolved from a monthly dosing schedule to individualized regimens.
💡
Conclusion & Impact:This paper will review the currently available anti-VEGF agents and evidence-based treatment strategies
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Over the past few years, anti-VEGF therapy has become a gold standard treatment for neovascular age-related macular degeneration. Treatment strategies have evolved from a monthly dosing schedule to individualized regimens. This paper will review the currently available anti-VEGF agents and evidence-based treatment strategies

Özet

Son yıllarda, anti-VEGF tedavisi neovasküler yaşa bağlı maküla dejenerasyonu tedavisinde altın standart olmuştur. Tedavi stratejileri de aylık uygulamalardan, kişiselleştirilmiş, gerektiğinde tedavi uygulamalarına yönelmiştir. Bu derlemede kullanılmakta olan tedavi yöntemleri ve uygulama stratejileri kanıta dayalı olarak sunulmuştur

🔖

Cite This Article

KAPRAN, Z., HELVACIOĞLU, F. (2015). Anti-VEGF Treatment in Age Realted Macular Degeneration. Retina-Vitreus, Cilt: 23 - Sayı: 0, 233–242. https://ajindex.com/articles/308044

References (15)

  1. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1992;99:933-43
  2. Vingerling JR, Dielemans I, Hofmann A et al. The prevalence of age-related maculopathy inRotterdam eye study. Ophthalmology 1995;102:205-10
  3. Bird AC, Bressler NM, Bressler SB, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. Surv Ophthalmol 1995;39:367-74
  4. Ferris FL 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984;102:1640-2
  5. Macular Photocoagulation Study Group. The influence of treatment coverage on the visual acuity of eyes treated with krypton laser for juxtafoveal choroidal neovascularisation. Arch Ophthalmol 1995;113:190-4
  6. Complications of Age-Related Macular Degeneration Prevention Trial Study Group. The Complications of Age-Related Macular Degeneration Prevention Trial (CAPT): rationale, design and methodology. Clin Trials 2004;1:91-107
  7. Treatment of Age-related Macular Degeneration With Photodynamic Therapy (TAP) Study Group.Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration With Verteporfin: One-Year Results of 2 Randomized Clinical Trials-TAP Report no.1 Arch Ophthalmol 1999;117:1329-45
  8. Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial-VIP report no
  9. Ophthalmology 2001;108:841-52
  10. Altan T, Kapran Z, Yalçın O, ve ark. Yaşa bağlı maküla dejenerasyonunda subfoveal koroidal neovaskülarizasyonun verteporfin ile fotodinamik tedavisinin orta ve uzun dönem sonuçları. Ret-Vit 2006;3:169-74
  11. Karaağaç H, Yanyalı A, Özmen D, ve ark. Yaşa bağlı maküla dejenerasyonlu olgularda fundus lezyonlarının görme keskinliği Üzerine Etkisi. Ret-Vit 2002;2:142-7
  12. Bressler SB Maguire MG Bressler NM Fine SL. The Macular Photocuagulation study grup the relationship of drusen and abnormalaties of RPE to the prognosis of ARMD. Arch Ophthalmol 1990;108:1442-7
  13. Bavbek T. Yaşa bağlı maküla dejeneresansı fizyopatoloji ve tedavide yeni görüşler. Ret-Vit 1993;2:197-203
  14. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permiability factor that promotes that promotes accumulation of ascites fluids. Science 1983;219:983-5
  15. Ferrara N, Henzel WJ. Pitui